Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Genmab A/S - American Depositary Shares
(NQ:
GMAB
)
31.70
-0.12 (-0.38%)
Streaming Delayed Price
Updated: 3:11 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genmab A/S - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
↗
September 16, 2024
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
September 15, 2024
From
Genmab A/S
Via
Business Wire
Expert Ratings For Genmab
↗
September 09, 2024
Via
Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
↗
September 03, 2024
Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
↗
August 26, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing.
Via
Chartmill
Decoding 10 Analyst Evaluations For Genmab
↗
August 20, 2024
Via
Benzinga
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
↗
August 05, 2024
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
What 8 Analyst Ratings Have To Say About Genmab
↗
August 01, 2024
Via
Benzinga
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024
From
Genmab A/S
Via
Business Wire
Genmab Announces Changes to its Executive Committee
August 16, 2024
From
Genmab A/S
Via
Business Wire
On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
↗
August 13, 2024
Via
Benzinga
What 8 Analyst Ratings Have To Say About Genmab
↗
July 15, 2024
Via
Benzinga
NASDAQ:GMAB, an undervalued stock with good fundamentals.
↗
July 01, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
10 Analysts Assess Genmab: What You Need To Know
↗
June 20, 2024
Via
Benzinga
GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
↗
August 05, 2024
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology...
Via
Benzinga
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
↗
August 05, 2024
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via
Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
↗
July 15, 2024
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably.
Via
Chartmill
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
June 28, 2024
From
Genmab A/S
Via
Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
↗
June 27, 2024
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.
Via
Benzinga
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
June 26, 2024
From
Genmab A/S
Via
Business Wire
7 Biotech Stocks to Buy on the Dip: June 2024
↗
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
↗
June 21, 2024
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
7 Stocks That Could Safely 10X by 2030
↗
June 06, 2024
Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align.
Via
InvestorPlace
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
June 03, 2024
From
Genmab A/S
Via
Business Wire
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
June 02, 2024
From
Genmab A/S
Via
Business Wire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
Genmab A/S
Via
Business Wire
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
May 24, 2024
Via
Benzinga
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Genmab A/S
Via
Business Wire
Genmab Completes Acquisition of ProfoundBio
May 21, 2024
From
Genmab A/S
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
